JP2018503649A5 - - Google Patents

Download PDF

Info

Publication number
JP2018503649A5
JP2018503649A5 JP2017539596A JP2017539596A JP2018503649A5 JP 2018503649 A5 JP2018503649 A5 JP 2018503649A5 JP 2017539596 A JP2017539596 A JP 2017539596A JP 2017539596 A JP2017539596 A JP 2017539596A JP 2018503649 A5 JP2018503649 A5 JP 2018503649A5
Authority
JP
Japan
Prior art keywords
crystalline
composition
compound
pyrrole
chlorophenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017539596A
Other languages
English (en)
Japanese (ja)
Other versions
JP7258460B2 (ja
JP2018503649A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/015829 external-priority patent/WO2016123574A1/en
Publication of JP2018503649A publication Critical patent/JP2018503649A/ja
Publication of JP2018503649A5 publication Critical patent/JP2018503649A5/ja
Application granted granted Critical
Publication of JP7258460B2 publication Critical patent/JP7258460B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017539596A 2015-01-30 2016-01-29 C21H22Cl2N4O2の結晶形態 Active JP7258460B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562110449P 2015-01-30 2015-01-30
US62/110,449 2015-01-30
PCT/US2016/015829 WO2016123574A1 (en) 2015-01-30 2016-01-29 Crystalline forms of c21h22ci2n4o2

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020063198A Division JP2020100674A (ja) 2015-01-30 2020-03-31 C21H22Cl2N4O2の結晶形態

Publications (3)

Publication Number Publication Date
JP2018503649A JP2018503649A (ja) 2018-02-08
JP2018503649A5 true JP2018503649A5 (OSRAM) 2019-02-14
JP7258460B2 JP7258460B2 (ja) 2023-04-17

Family

ID=56544441

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2017539596A Active JP7258460B2 (ja) 2015-01-30 2016-01-29 C21H22Cl2N4O2の結晶形態
JP2020063198A Pending JP2020100674A (ja) 2015-01-30 2020-03-31 C21H22Cl2N4O2の結晶形態
JP2021195403A Pending JP2022033866A (ja) 2015-01-30 2021-12-01 C21H22Cl2N4O2の結晶形態
JP2023081553A Withdrawn JP2023096080A (ja) 2015-01-30 2023-05-17 C21H22Cl2N4O2の結晶形態
JP2025050047A Pending JP2025089464A (ja) 2015-01-30 2025-03-25 C21H22Cl2N4O2の結晶形態

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2020063198A Pending JP2020100674A (ja) 2015-01-30 2020-03-31 C21H22Cl2N4O2の結晶形態
JP2021195403A Pending JP2022033866A (ja) 2015-01-30 2021-12-01 C21H22Cl2N4O2の結晶形態
JP2023081553A Withdrawn JP2023096080A (ja) 2015-01-30 2023-05-17 C21H22Cl2N4O2の結晶形態
JP2025050047A Pending JP2025089464A (ja) 2015-01-30 2025-03-25 C21H22Cl2N4O2の結晶形態

Country Status (12)

Country Link
US (6) US9676746B2 (OSRAM)
EP (2) EP3250562B1 (OSRAM)
JP (5) JP7258460B2 (OSRAM)
CN (2) CN116854662A (OSRAM)
AU (5) AU2016211246B2 (OSRAM)
CA (2) CA2975048C (OSRAM)
ES (1) ES3009552T3 (OSRAM)
HK (1) HK1244274A1 (OSRAM)
MX (1) MX382289B (OSRAM)
NZ (2) NZ734041A (OSRAM)
SG (2) SG11201705924RA (OSRAM)
WO (1) WO2016123574A1 (OSRAM)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015095842A2 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers
ES3009552T3 (en) * 2015-01-30 2025-03-27 Biomed Valley Discoveries Inc Crystalline 4-(5-chloro-2-isopropylaminopyridin-4-yl)-1h-pyrrole-2-carboxylic acid [1-(3-chlorophenyl)-2-hydroxyethyl]amide hydrochloride salt
HK1243357A1 (zh) * 2016-01-27 2018-07-13 江苏恒瑞医药股份有限公司 一种含有喹啉衍生物或其盐的药物组合物的制备方法
WO2021020841A1 (en) * 2019-07-29 2021-02-04 Standigm Inc. Composition for preventing or treating metabolic liver disease
US20230024584A1 (en) * 2019-11-20 2023-01-26 University Of Kentucky Research Foundation Anti-cancer compositions and methods
WO2023169480A1 (zh) * 2022-03-08 2023-09-14 甘李药业股份有限公司 氘代化合物,及其制备方法和应用
TW202400572A (zh) * 2022-03-24 2024-01-01 美商生物醫學谷探索公司 Erk的吡咯抑制劑之氘化類似物、其合成及其中間物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599331A (en) 1984-12-24 1986-07-08 Syntex (U.S.A.) Inc. Etianic acids as antiangiogenics
EP0245357B1 (en) 1985-10-23 1991-08-07 The Upjohn Company Angiostatic steroids
US4771042A (en) 1985-11-25 1988-09-13 The Upjohn Company Inhibition of angiogenesis involving the coadministration of steroids with heparin or heparin fragments
WO1990015816A1 (en) 1989-06-16 1990-12-27 The Upjohn Company Suramin type compounds and angiostatic steroids to inhibit angiogenesis
EP1236470A3 (en) 1991-11-22 2004-09-01 Alcon Laboratories, Inc. Angiostatic steroids
KR20010111298A (ko) * 2000-02-05 2001-12-17 버텍스 파마슈티칼스 인코포레이티드 Erk의 억제제로서 유용한 피라졸 조성물
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
WO2003091246A1 (en) * 2002-04-26 2003-11-06 Vertex Pharmaceuticals Incorporated Pyrrole derivatives as inhibitors of erk2 and uses thereof
JP5132305B2 (ja) 2004-05-14 2013-01-30 バーテックス ファーマシューティカルズ インコーポレイテッド Erkプロテインキナーゼのインヒビターとしてのピロール化合物、それらの合成、およびそれらの中間体
US7582623B2 (en) 2004-05-20 2009-09-01 The Regents Of The University Of California Photoactive metal nitrosyls for blood pressure regulation and cancer therapy
PL2091910T3 (pl) 2006-12-06 2015-02-27 Conatus Pharmaceuticals Inc Postacie krystaliczne kwasu (3S)-3-[N-(N’-(2-tert-butylofenylo)oksamylo)alaninylo]amino-5-(2’,3’,5’,6’-tetrafluorofenoksy)-4-oksopentanowego
WO2014047167A1 (en) * 2012-09-18 2014-03-27 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
US9227969B2 (en) 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
ES3009552T3 (en) * 2015-01-30 2025-03-27 Biomed Valley Discoveries Inc Crystalline 4-(5-chloro-2-isopropylaminopyridin-4-yl)-1h-pyrrole-2-carboxylic acid [1-(3-chlorophenyl)-2-hydroxyethyl]amide hydrochloride salt

Similar Documents

Publication Publication Date Title
JP2018503649A5 (OSRAM)
JP2015512942A5 (OSRAM)
JP2019517487A5 (OSRAM)
JP2013522232A5 (OSRAM)
JP2014506907A5 (OSRAM)
JP2018531280A5 (OSRAM)
JP2014516360A5 (OSRAM)
BRPI0813625A2 (pt) Imidazo-[1,2b]-piridozinas 2,3,7-substituídos para tratamento de doenças mediadas por alzk4 ou alk5
JP2016522266A5 (OSRAM)
JP2014526469A5 (OSRAM)
JP2015501799A5 (OSRAM)
JP2012533570A5 (OSRAM)
JP2014507455A5 (OSRAM)
RU2015106137A (ru) Кристаллический полиморф 4-[5-(пиридин-4-ил)-1н-1,2,4-триазол-3-ил]-пиридин-2-карбонитрила и способ его получения
JP2019501140A5 (OSRAM)
PH12016501651A1 (en) Triazine compound and use thereof for medical purposes
RU2015103065A (ru) Кристаллическая форма i дималеата ингибитора тирозинкиназы и способ ее получения
JP2009511519A5 (OSRAM)
WO2014011971A3 (en) Deuterated carfilzomib
RU2017134709A (ru) П-толуолсульфонат для ингибитора мек-киназы и его кристаллическая форма, и способ его получения
JP2010514725A5 (OSRAM)
EP4477222A3 (en) Crystalline 4-(5-chloro-2-isopropylaminopyridin-4-yl)-1h-pyrrole-2-carboxylic acid [1-(3-chlorophenyl)-2-hydroxyethyl]amide hydrochloride salt
KR20180111797A (ko) 퀴놀론 유사체의 결정형 및 그것의 염
JP2016515550A5 (OSRAM)
JP2015518048A5 (OSRAM)